News Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 17:27:37 04/08/2026 +03			5-day change	1st Jan Change
476.49 ^USD	+1.23%		-1.51%	+6.54%

03:39pm	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
01:56pm	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT

All News

Mentions Relevance

03:39pm	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
01:56pm	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
01:36pm	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
01:35pm	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
01:34pm	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
01:32pm	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
01:30pm	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
08-04	Vertex Pharmaceuticals Incorporated, Q2 2026 Earnings Call, Aug 03, 2026
08-04	Vertex Pharmaceuticals Bumps Up Fiscal Year Outlook on Growth of Cystic Fibrosis Drugs	DJ
08-03	Vertex: Q2 Earnings Snapshot	AQ
08-03	Vertex Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance	MT
08-03	(VRTX) Vertex Pharmaceuticals Now Expects 2026 Revenue Range $13.1B-$13.2B, vs. FactSet Est of $13.06B	MT
08-03	Vertex raises annual revenue forecast on cystic fibrosis drugs strength	RE
08-03	Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Reports Q2 Revenue $3.33B, vs. FactSet Est of $3.23B	MT
08-03	Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q2 Adjusted EPS $4.73 per Share, vs. FactSet Est of $4.74	MT
08-03	Vertex Reports Second Quarter 2026 Financial Results	BU
08-03	Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for Full Year 2026	CI
08-03	Vertex Pharmaceuticals Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-21	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
07-20	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT
07-13	UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating	MT
07-09	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570	MT
07-08	Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580	MT
07-07	Vertex to Announce Second Quarter 2026 Financial Results on August 3rd	BU
07-07	IBT company Crinetics to be acquired by Vertex for USD10 billion	AN